Development, validation, and routine application of a high-performance liquid chromatography method coupled with a single mass detector for quantification of itraconazole, voriconazole, and posaconazole in human plasma

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 8, 2010, Pages 3408-3413

  Baietto, Lorena ^a   D'Avolio, Antonio ^a   Ventimiglia, Giusi ^a   De Rosa, Francesco Giuseppe ^a   Siccardi, Marco ^a   Simiele, Marco ^a   Sciandra, Mauro ^a   Di Perri, Giovanni ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETONITRILE; ITRACONAZOLE; POSACONAZOLE; QUINOXALINE; VORICONAZOLE;

ACCURACY; ARTICLE; DRUG BLOOD LEVEL; DRUG MONITORING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MYCOSIS; PRECIPITATION; PRIORITY JOURNAL; QUANTITATIVE ASSAY;

ANTIFUNGAL AGENTS; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; ITRACONAZOLE; MASS SPECTROMETRY; PYRIMIDINES; REFERENCE STANDARDS; TRIAZOLES;

EID: 77955396579     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01807-09     Document Type: Article

References (47)

1. Andes, D., K. Marchillo, R. Conklin, G. Krishna, F. Ezzet, A. Cacciapuoti, and D. Loebenberg. 2004. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob. Agents Chemother. 48:137-142.
2. Andes, D., K. Marchillo, T. Stamstad, and R. Conklin. 2003. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob. Agents Chemother. 47:3165-3169.
3. Barone, J. A., J. G. Koh, R. H. Bierman, J. L. Colaizzi, K. A. Swanson, M. C. Gaffar, B. L. Moskovitz, W. Mechlinski, and V. Van de Velde. 1993. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob. Agents Chemother. 37:778-784.
4. Boogaerts, M. A., G. E. Verhoef, P. Zachee, H. Demuynck, L. Verbist, and K. De Beule. 1989. Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses 32(Suppl. 1):103-108.
5. Boyd, A. E., S. Modi, S. J. Howard, C. B. Moore, B. G. Keevil, and D. W. Denning. 2004. Adverse reactions to voriconazole. Clin. Infect. Dis. 39:1241-1244.
6. Brandsteterova, E., P. Kubalec, A. Rady, and V. Krcmery. 1995. Determination of itraconazole and its metabolite in plasma using SPE-HPLC. Pharmazie 50:597-599.
7. Breadmore, M. C., A. Prochazkova, R. Theurillat, and W. Thormann. 2003. Determination of itraconazole and hydroxyitraconazole in human serum and plasma by micellar electrokinetic chromatography. J. Chromatogr. A 1014: 57-70. (Pubitemid 37311158)
8. Chhun, S., E. Rey, A. Tran, O. Lortholary, G. Pons, and V. Jullien. 2007. Simultaneous quantification of voriconazole and posaconazole in human plasma by high-performance liquid chromatography with ultra-violet detection. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 852:223-228.
9. Darouiche, R. O., A. Setoodeh, and E. J. Anaissie. 1995. Potential use of a simplified method for determination of itraconazole levels in plasma and esophageal tissue by using high-performance liquid chromatography. Antimicrob. Agents Chemother. 39:757-759.
10. FDA. 2001. Guidance for industry: bioanalytical method validation. http: //www.fda.gov/cder/guidance/4252fnl.pdf. FDA, Silver Spring, MD.
11. Gage, R., and D. A. Stopher. 1998. A rapid HPLC assay for voriconazole in human plasma. J. Pharm. Biomed. Anal. 17:1449-1453.
12. Glasmacher, A., C. Hahn, C. Leutner, E. Molitor, E. Wardelmann, C. Losem, T. Sauerbruch, G. Marklein, and I. G. Schmidt-Wolf. 1999. Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses 42:443-451. (Pubitemid 29470385)
13. Gordien, J. B., A. Pigneux, S. Vigouroux, R. Tabrizi, I. Accoceberry, J. M. Bernadou, A. Rouault, M. C. Saux, and D. Breilh. 2009. Simultaneous determination of five systemic azoles in plasma by high-performance liquid chromatography with ultraviolet detection. J. Pharm. Biomed. Anal. 50:932-938.
14. Hardin, T. C., J. R. Graybill, R. Fetchick, R. Woestenborghs, M. G. Rinaldi, and J. G. Kuhn. 1988. Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob. Agents Chemother. 32:1310-1313.
15. Khoschsorur, G., F. Fruehwirth, and S. Zelzer. 2005. Isocratic high-performance liquid chromatographic method with ultraviolet detection for simultaneous determination of levels of voriconazole and itraconazole and its hydroxy metabolite in human serum. Antimicrob. Agents Chemother. 49: 3569-3571.
16. KKGT. 2009. International Quality Control Program for Antifungal Drugs. KKGT, Den Haag, Netherlands. http://www.kkgt.nl/English%20Version.htm. Accessed 11 November 2009.
17. Koks, C. H., R. W. Sparidans, G. Lucassen, K. M. Crommentuyn, and J. H. Beijnen. 2002. Selective high-performance liquid chromatographic assay for itraconazole and hydroxyitraconazole in plasma from human immunodeficiency virus-infected patients. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 767:103-110.
18. Lacroix, C., F. Wojciechowski, and P. Danger. 1995. Simultaneous determination of itraconazole, hydroxy-itraconazole and amphotericin B in human plasma by HPLC with photodiode array detection. Ann. Biol. Clin. (Paris) 53:293-297.
19. Lampe, D., S. Kreutzberg, and H. J. Prumke. 1994. Therapeutic drug monitoring of itraconazole - a report of experiences. Mycoses 37(Suppl. 2):34-39. (In German.)
20. Langman, L. J., and F. Boakye-Agyeman. 2007. Measurement of voriconazole in serum and plasma. Clin. Biochem. 40:1378-1385.
21. Lazarus, H. M., J. L. Blumer, S. Yanovich, H. Schlamm, and A. Romero. 2002. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J. Clin. Pharmacol. 42:395-402.
22. Lestner, J. M., S. A. Roberts, C. B. Moore, S. J. Howard, D. W. Denning, and W. W. Hope. 2009. Toxicodynamics of itraconazole: implications for therapeutic drug monitoring. Clin. Infect. Dis. 49:928-930.
23. Mathew, B. P., and M. Nath. 2009. Recent approaches to antifungal therapy for invasive mycoses. ChemMedChem 4:310-323.
24. Michael, C., J. Teichert, and R. Preiss. 2008. Determination of voriconazole in human plasma and saliva using high-performance liquid chromatography with fluorescence detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 865:74-80.
25. Nakagawa, S., R. Suzuki, R. Yamazaki, Y. Kusuhara, S. Mitsumoto, H. Kobayashi, S. Shimoeda, S. Ohta, and S. Yamato. 2008. Determination of the antifungal agent voriconazole in human plasma using a simple columnswitching high-performance liquid chromatography and its application to a pharmacokinetic study. Chem. Pharm. Bull. (Tokyo) 56:328-331.
26. Ohkubo, T., and T. Osanai. 2005. Determination of itraconazole in human plasma by high-performance liquid chromatography with solid-phase extraction. Ann. Clin. Biochem. 42:94-98.
27. Pascual, A., T. Calandra, S. Bolay, T. Buclin, J. Bille, and O. Marchetti. 2008. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin. Infect. Dis. 46:201-211.
28. Pascual, A., V. Nieth, T. Calandra, J. Bille, S. Bolay, L. A. Decosterd, T. Buclin, P. A. Majcherczyk, D. Sanglard, and O. Marchetti. 2007. Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods. Antimicrob. Agents Chemother. 51: 137-143.
29. Pehourcq, F., C. Jarry, and B. Bannwarth. 2004. Direct injection HPLC micro method for the determination of voriconazole in plasma using an internal surface reversed-phase column. Biomed. Chromatogr. 18:719-722.
30. Poirier, J. M., and G. Cheymol. 1998. Optimisation of itraconazole therapy using target drug concentrations. Clin. Pharmacokinet. 35:461-473.
31. Poirier, J. M., and G. Cheymol. 1997. A rapid and specific liquid chromatographic assay for the determination of itraconazole and hydroxyitraconazole in plasma. Ther. Drug Monit. 19:247-248.
32. Redmann, S., and B. G. Charles. 2006. A rapid HPLC method with fluorometric detection for determination of plasma itraconazole and hydroxyitraconazole concentrations in cystic fibrosis children with allergic bronchopulmonary aspergillosis. Biomed. Chromatogr. 20:343-348.
33. Rhim, S. Y., J. H. Park, Y. S. Park, D. S. Kim, M. H. Lee, L. M. Shaw, and J. S. Kang. 2009. A sensitive validated LC-MS/MS method for quantification of itraconazole in human plasma for pharmacokinetic and bioequivalence study in 24 Korean volunteers. Pharmazie 64:71-75.
34. Rifai, N., M. Sakamoto, O. Platt, and C. Brugnara. 1995. A high-performance liquid chromatographic assay for the determination of itraconazole concentration using solid-phase extraction and small sample volume. Ther. Drug Monit. 17:522-525.
35. Shen, J. X., G. Krishna, and R. N. Hayes. 2007. A sensitive liquid chromatography and mass spectrometry method for the determination of posaconazole in human plasma. J. Pharm. Biomed. Anal. 43:228-236.
36. Simmel, F., J. Soukup, A. Zoerner, J. Radke, and C. Kloft. 2008. Development and validation of an efficient HPLC method for quantification of voriconazole in plasma and microdialysate reflecting an important target site. Anal. Bioanal Chem. 392:479-488.
37. Srivatsan, V., A. K. Dasgupta, P. Kale, R. R. Datla, D. Soni, M. Patel, R. Patel, and C. Mavadhiya. 2004. Simultaneous determination of itraconazole and hydroxyitraconazole in human plasma by high-performance liquid chromatography. J. Chromatogr. A 1031:307-313. (Pubitemid 38264248)
38. Stopher, D. A., and R. Gage. 1997. Determination of a new antifungal agent, voriconazole, by multidimensional high-performance liquid chromatography with direct plasma injection onto a size-exclusion column. J. Chromatogr. B Biomed. Sci. Appl. 691:441-448.
39. Storzinger, D., C. Lichtenstern, S. Swoboda, M. A. Weigand, and T. Hoppe-Tichy. 2008. Posaconazole in intensive care patients I: invasive fungal infections in surgical intensive care and case presentation. Mycoses 51(Suppl. 2):52-57.
40. Storzinger, D., S. Swoboda, C. Lichtenstern, C. Muller, M. A. Weigand, and T. Hoppe-Tichy. 2008. Development and validation of a high-performance liquid chromatography assay for posaconazole utilizing solid-phase extraction. Clin. Chem. Lab. Med. 46:1747-1751.
41. Tan, K., N. Brayshaw, K. Tomaszewski, P. Troke, and N. Wood. 2006. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J. Clin. Pharmacol. 46:235-243.
42. Taylor, P. J. 2005. Matrix effects: the Achilles heel of quantitative highperformance liquid chromatography-electrospray-tandem mass spectrometry. Clin. Biochem. 38:328-334.
43. University of Turin. 2009. Therapeutic drug monitoring-Turin. University of Turin, Turin, Italy. http://www.tdm-torino.org/. Accessed 15 November 2009.
44. Ullmann, A. J., O. A. Cornely, A. Burchardt, R. Hachem, D. P. Kontoyiannis, K. Topelt, R. Courtney, D. Wexler, G. Krishna, M. Martinho, G. Corcoran, and I. Raad. 2006. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob. Agents Chemother. 50:658-666.
45. Uno, T., M. Shimizu, K. Sugawara, and T. Tateishi. 2006. Sensitive determination of itraconazole and its active metabolite in human plasma by column-switching high-performance liquid chromatography with ultraviolet detection. Ther. Drug Monit. 28:526-531.
46. Wong, J. W., U. R. Nisar, and K. H. Yuen. 2003. Liquid chromatographic method for the determination of plasma itraconazole and its hydroxy metabolite in pharmacokinetic/bioavailability studies. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 798:355-360.
47. Worth, L. J., C. C. Blyth, D. L. Booth, D. C. Kong, D. Marriott, M. Cassumbhoy, J. Ray, M. A. Slavin, and J. R. Wilkes. 2008. Optimizing antifungal drug dosing and monitoring to avoid toxicity and improve outcomes in patients with haematological disorders. Intern. Med. J. 38:521-537.